Medical Staff Pulse Newsletter

FDA Warns About Possible Cancer Risk With Weight Drug Lorcaserin

The U.S. Food and Drug Administration (FDA) is alerting the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine Belviq, Belviq XR (lorcaserin). At this time, the cause of the cancer is uncertain, and the FDA cannot conclude that lorcaserin contributes to the cancer risk. However, the agency wanted to make the public aware of this potential risk.

Lorcaserin is a prescription medicine approved by the FDA in 2012 for use with a reduced-calorie diet and increased physical activity to help weight loss in adults who are obese or are overweight and have weight-related medical problems. Lorcaserin works by increasing feelings of fullness so that less food is eaten. It is available as a tablet (Belviq) and an extended-release tablet (Belviq XR).

The FDA website has more information.